Arrowhead Pharmaceuticals, Inc. (ARWR) Financial Ratios
29 years of historical data (1997–2025) · Healthcare · Biotechnology
EV/EBITDA
90.41
↑+133% vs avg
5yr avg: 38.87
30Y Low38.9·High39.0
P/FCF
↓
69.58
↑+90% vs avg
5yr avg: 36.62
30Y Low17.3·High142.5
P/B Ratio
↓
20.71
↑+87% vs avg
5yr avg: 11.09
30Y Low0.0·High16.8
ROE
↑
-0.5%
↓+99% vs avg
5yr avg: -76.9%
30Y Low-251%·High40%
Debt/EBITDA
3.00
+0% vs avg
5yr avg: 3.00
30Y Low3.0·High3.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ARWR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arrowhead Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 69.6x P/FCF, 90% above the 5-year average of 36.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.9B | $4.6B | $2.3B | $2.9B | $3.5B | $6.5B | $4.3B | $2.8B | $1.6B | $320M | $449M |
| Enterprise Value | $11.1B | $4.8B | $3.1B | $3.1B | $3.5B | $6.3B | $4.2B | $2.6B | $1.6B | $298M | $366M |
| P/E Ratio → | -6389.34 | — | — | — | — | — | — | 40.84 | — | — | — |
| P/S Ratio | 13.16 | 5.56 | 653.40 | 11.92 | 14.33 | 46.84 | 49.29 | 16.46 | 99.33 | 10.19 | 2834.05 |
| P/B Ratio | 20.71 | 9.16 | 12.14 | 9.99 | 8.33 | 15.84 | 9.39 | 11.39 | 16.83 | 3.96 | 4.72 |
| P/FCF | 69.58 | 29.41 | — | — | — | 43.84 | — | 17.26 | — | — | — |
| P/OCF | 60.79 | 25.69 | — | — | — | 37.81 | — | 16.06 | — | — | — |
P/E links to full P/E history page with 30-year chart
ARWR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Arrowhead Pharmaceuticals, Inc.'s enterprise value stands at 90.4x EBITDA, 133% above its 5-year average of 38.9x. The Healthcare sector median is 14.4x, placing the stock at a 528% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.73 | 864.39 | 13.05 | 14.22 | 45.69 | 47.90 | 15.15 | 97.60 | 9.48 | 2312.12 |
| EV / EBITDA | 90.41 | 38.87 | — | — | — | — | — | 38.96 | — | — | — |
| EV / EBIT | 112.41 | 33.73 | — | — | — | — | — | 41.79 | — | — | — |
| EV / FCF | — | 30.30 | — | — | — | 42.76 | — | 15.88 | — | — | — |
ARWR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Arrowhead Pharmaceuticals, Inc. earns an operating margin of 11.9%. Operating margins have expanded from -85.2% to 11.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -0.5% indicates the company is currently destroying shareholder equity. ROIC of 9.3% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.1% | 97.1% | -423.7% | 94.8% | 95.7% | — | — | — | — | — | — |
| Operating Margin | 11.9% | 11.9% | -16927.1% | -85.2% | -73.4% | -107.8% | -105.9% | 36.3% | -346.5% | -117.8% | -51627.1% |
| Net Profit Margin | -0.2% | -0.2% | -16882.4% | -85.3% | -72.4% | -101.9% | -96.1% | 40.3% | -337.3% | -109.5% | -51614.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.5% | -0.5% | -250.7% | -58.2% | -42.6% | -32.4% | -24.0% | 40.1% | -61.8% | -39.1% | -79.9% |
| ROA | -0.1% | -0.1% | -62.9% | -28.2% | -25.1% | -22.9% | -19.4% | 29.5% | -50.5% | -29.6% | -62.8% |
| ROIC | 9.3% | 9.3% | -60.1% | -32.3% | -41.7% | -37.9% | -38.6% | 102.4% | -66.6% | -78.2% | -295.1% |
| ROCE | 8.8% | 8.8% | -70.9% | -33.8% | -32.0% | -28.5% | -25.4% | 34.8% | -60.6% | -39.4% | -74.7% |
ARWR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Arrowhead Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 3.0x, which is moderately leveraged (9% below the sector average of 3.3x). Net debt stands at $140M ($366M total debt minus $227M cash). Interest coverage of just 1.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.73 | 0.73 | 4.46 | 1.34 | 0.20 | 0.06 | 0.05 | — | 0.02 | 0.03 | 0.03 |
| Debt / EBITDA | 3.00 | 3.00 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.28 | 3.92 | 0.95 | -0.06 | -0.39 | -0.27 | -0.91 | -0.29 | -0.28 | -0.87 |
| Net Debt / EBITDA | 1.14 | 1.14 | — | — | — | — | — | -3.38 | — | — | — |
| Debt / FCF | — | 0.89 | — | — | — | -1.08 | — | -1.38 | — | — | — |
| Interest Coverage | 1.58 | 1.58 | -17.93 | -10.27 | — | — | — | — | — | — | — |
ARWR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Arrowhead Pharmaceuticals, Inc.'s current ratio of 4.86x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.98x to 4.86x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.86 | 4.86 | 6.74 | 3.98 | 2.92 | 2.62 | 7.92 | 2.73 | 6.37 | 3.63 | 3.53 |
| Quick Ratio | 4.86 | 4.86 | 6.74 | 3.98 | 3.07 | 2.59 | 7.82 | 2.70 | 6.27 | 3.58 | 3.48 |
| Cash Ratio | 4.70 | 4.70 | 6.60 | 3.83 | 2.71 | 2.51 | 7.76 | 2.67 | 6.19 | 3.51 | 3.33 |
| Asset Turnover | — | 0.60 | 0.00 | 0.31 | 0.35 | 0.19 | 0.17 | 0.48 | 0.14 | 0.30 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 3.00 | — | — | 2.12 | 27.07 | 3.51 | 1.43 | 7.40 | 0.79 | 172.90 |
ARWR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 2.4% | — | — | — |
| FCF Yield | 1.4% | 3.4% | — | — | — | 2.3% | — | 5.8% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $134M | $120M | $107M | $105M | $104M | $101M | $99M | $84M | $74M | $61M |
Peer Comparison
Compare ARWR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARWRYou | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 MDGL | $12B | -41.6 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
Full ARWR Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ARWR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARWR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARWR vs ALNY
Side-by-side business, growth, and profitability comparison vs Alnylam Pharmaceuticals, Inc..
Start ComparisonARWR — Frequently Asked Questions
Quick answers to the most common questions about buying ARWR stock.
What is Arrowhead Pharmaceuticals, Inc.'s P/E ratio?
Arrowhead Pharmaceuticals, Inc.'s current P/E ratio is -6389.3x. The historical average is 20.9x.
What is Arrowhead Pharmaceuticals, Inc.'s EV/EBITDA?
Arrowhead Pharmaceuticals, Inc.'s current EV/EBITDA is 90.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 38.9x.
What is Arrowhead Pharmaceuticals, Inc.'s ROE?
Arrowhead Pharmaceuticals, Inc.'s return on equity (ROE) is -0.5%. The historical average is -76.7%.
Is ARWR stock overvalued?
Based on historical data, Arrowhead Pharmaceuticals, Inc. is trading at a P/E of -6389.3x. Compare with industry peers and growth rates for a complete picture.
What are Arrowhead Pharmaceuticals, Inc.'s profit margins?
Arrowhead Pharmaceuticals, Inc. has 97.1% gross margin and 11.9% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Arrowhead Pharmaceuticals, Inc. have?
Arrowhead Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 3.0x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.